On July 7, 2022 Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, reported that the first patient was treated at the David C. Pratt Cancer Center at Mercy Hospital St. Louis on July 5th with the MEVION S250i Proton Therapy System (Press release, Mevion Medical Systems, JUL 7, 2022, View Source [SID1234616546]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The new Mercy Proton Therapy Center is one of only 40 treating centers in the U.S. Thanks to the compact size of the MEVION S250i, Mercy was able to integrate the addition into the existing radiation oncology department, enabling the hospital to share existing resources and maintain a full continuum of care for patients.
A ribbon-cutting event was held on June 30 with members from Mercy and Mevion Medical Systems.
"We know patients have choices when it comes to cancer care and when they choose Mercy, we want them to know they have access to all the options for care," said Dr. Robert Frazier, division chief of radiation oncology at Mercy Hospital St. Louis. "Each patient is unique so no two treatment plans will be the same. At the David C. Pratt Cancer Center, we now have all the most advanced radiation therapy technologies, both Cyberknife and proton therapy, making sure we offer what’s best for each individual during their cancer therapy."
The center features Mevion’s industry-leading HYPERSCAN pencil beam scanning technology and Adaptive Aperture pMLC. The powerful duo delivers faster and more precise, therapeutic doses of radiation to tumors while preserving surrounding healthy tissue and organs at risk, making proton therapy an ideal treatment choice for tumors near sensitive parts of the body such as the head and neck, spinal cord, breasts, esophagus, prostate, lung, bone, gastrointestinal, stomach, colon, and bladder.
The MEVION S250i system at Mercy also integrates the CBCT imaging system and the C-RAD Catalyst PT surface-guided tracking system, enabling a cutting-edge Image-Guided Proton Therapy configuration for high-precision patient positioning and intra-fraction motion management.
"We congratulate Mercy for starting treatment with the Mevion proton therapy system," said Tina Yu, chief executive officer and president of Mevion Medical Systems. "Mevion is proud to be a part of Mercy’s dedication to offering this state-of-the-art cancer treatment in St. Louis and the surrounding area."
Mevion is the system provider for 60% of the clinical single-room proton centers in the U.S. and has treated over 7,000 patients worldwide.